1st Biotherapeutics, Inc.

YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors. Under the terms of the agreement, MSD will provide KEYTRUDA to be used in combination with FB849 for the planned Phase I/II study. “We are very pleased to mark the next stage of FB849’s development with this exciting collaboration. We are hopeful that combining FB849 with KEYTRUDA may induce an effective anti-tumor response and show an additive benefit for patients with advanced solid tumors,” said Jamie Jae Eun Kim, Ph.D., Founder and Chief Executive Officer of 1ST Biotherapeutics. “This collaboration will play an important role in the advancement of this program and marks further validation of our differentiated drug discovery and development approach. We will continue to leverage our expertise and dedication to bring innovative therapeutics to patients with high unmet medical needs.” The Phase I/II study (NCT05761223) is a first-in-human, multicenter, open-label study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of FB849 alone as a monotherapy and in combination with KEYTRUDA for the treatment of advanced solid tumors. The recruitment in the clinical study is expected in the second half of 2023. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ### About FB849 FB849 is a 1ST Biotherapeutic’s proprietary small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) as a novel next-generation immuno-oncology agent. Throughout the preclinical studies, it has been demonstrated that FB849’s highly selective inhibition of HPK1 induces potent anti-cancer immunity via cross-spectrum immune cell invigoration, including T cells, B cells, dendritic cells, and macrophages, with robust and durable effects in tumor growth inhibition. About 1ST Biotherapeutics 1ST Biotherapeutics is a science-driven biopharmaceutical company focused on the development of breakthrough therapies in neurodegenerative diseases, immuno-oncology, and rare diseases. Founded in 2016, 1ST Biotherapeutics has rapidly developed a deep pipeline of first-in-class investigational therapeutics with clear mechanisms for proper disease modification and excellent pharmacological properties. 1ST Biotherapeutics is based in Yongin, South Korea. For more information, please visit 1stbio.com. Contact 1ST Biotherapeutics, Inc. info@1stbio.com Tel. +82 31 8023 5332 Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners info@akampion.com Tel. +49 40 88 16 59 64 /Tel. +49 30 23 63 27 68

DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Artificial Intelligence (Ai) Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Artificial Intelligence (AI) Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in artificial intelligence partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Artificial intelligencepartnering contract documents Top artificial intelligence deals by value The Global Artificial Intelligence (AI) Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter artificial intelligencepartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligencetechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest artificial intelligence, oligonucletides including aptamers agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all artificial intelligence partnering deals announced since 2010 including financial terms where available including over 950 links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of artificial intelligence dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading artificial intelligence deals since 2010. Deals are listed by headline value, signed by big pharma, most active artificial intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 lists artificial intelligence deals by technology type announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by artificial intelligence partnering company A-Z, deal type definitions and artificial intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of artificial intelligence technologies and products. Report scope Global Artificial Intelligence Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to artificial intelligence trends and structure of deals entered into by leading companies worldwide. Global Artificial Intelligence Partnering Terms and Agreements includes: Trends in artificial intelligence dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 850 artificial intelligence deals The leading artificial intelligence deals by value since 2010 Most active artificial intelligence dealmakers since 2010 The leading artificial intelligence partnering resources In Global Artificial Intelligence Partnering Terms and Agreements, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned HistoIndex Medicines and Healthcare Products Regulatory Agency Boehringer Ingelheim Worthington Biochemical Corporation Loop Insights Roux Institute Wyss Institute Endpoint Health EndPoint Technologies MILA International Lore IO CoreBiome Relation Therapeutics DecisionQ KBP BioSciences AUM Biosciences SOM Biotech Vir Biotechnology 1ST Biotherapeutics BurstIQ Covaris Genesis Therapeutics C4X Discovery Atomwise IrisVision PolarisQB ChemDiv Adaptive Biotechnologies Kebotix AltaML Medial Reveal Biosciences Medial EarlySign Global Good Fund Mendel Health For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets